Table 2.

Adverse events

	Grade 1 N (%)	Grade 2 N (%)	Grade 3 N (%)
Nausea	1 (5.6)	1 (5.6)	0
Headache	1 (5.6)	0	0
Chills	2 (11.1)	0	0
Nasal congestion	1 (5.6)	0	0
Fatigue	4 (22.2)	3 (16.6)	0
Constipation	1 (5.6)	0	0
Hypersomnia	0	2 (11.1)	0
Hypophosphatemia	0	2 (11.1)	0
Anemia	0	1 (5.6)	1 (5.6)
Lung infection	0	0	1 (5.6)
Dehydration	1 (5.6)	0	1 (5.6)
Hypotension	1 (5.6)	0	1 (5.6)
Sinus tachycardia	1 (5.6)	0	0
Atrioventricular block	1 (5.6)	0	0
Ear pain	0	1 (5.6)	0
Abdominal pain	1 (5.6)	1 (5.6)	0
Diarrhea	2 (11.1)	0	0
Gastroesophageal reflux	1 (5.6)	0	0
Hemorrhoidal hemorrhage	1 (5.6)	0	0
Vomiting	2 (11.1)	1 (5.6)	0
Edema limbs	2 (11.1)	0	0
Fever	1 (5.6)	0	0
Flu-like symptoms	8	3	0
Malaise	0	1 (5.6)	0
Pain	1 (5.6)	0	0
Urinary tract infection	0	1 (5.6)	0
Injection-site reaction	22 (100)	7 (38.8)	0
Creatinine increased	1 (5.6)	0	0
Lymphocyte count decreased	0	1 (5.6)	2 (11.1)
Weight loss	1 (5.6)	1 (5.6)	0
Anorexia	1 (5.6)	2 (11.1)	0
Hyperglycemia	2 (11.1)	0	0
Hyponatremia	2 (11.1)	0	0
Hypophosphatemia	0	1 (5.6)	0
Arthralgia	0	1 (5.6)	0
Back pain	3 (16.7)	0	0
Myalgia	1 (5.6)	1 (5.6)	0
Non-cardiac chest pain	1 (5.6)	0	0
Dizziness	3 (16.7)	0	0

All adverse events are shown. N=number of events. There were no grade 4 treatment-related adverse events. Adverse event grade is according to the National Cancer Institute Common Terminology Criteria for Adverse Events V.5.0.